GlassScriptPhysician profile
Edwin Brady Locke
NPI 1578574729
$1,763.24
in general payments reported to CMS, 2019-2025
24 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $178 · 2021: $337 · 2022: $303 · 2023: $448 · 2024: $163 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $440.21 | 2019-2022 | |
| Axonics, INC. | $352.93 | 2023 | Axonics, Bulkamid |
| Astellas Pharma US INC | $167.33 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $136.41 | 2019-2022 | |
| Amgen INC. | $111.62 | 2019-2025 | Evenity, Prolia |
| Radius Health, INC. | $83.32 | 2024-2025 | Tymlos |
| Allergan, INC. | $61.33 | 2019-2020 | |
| Daiichi Sankyo INC. | $60.18 | 2021-2024 | Injectafer |
| Coopersurgical, INC. | $45.90 | 2020 | |
| Organon LLC | $41.26 | 2022-2024 | |
| Depuy Synthes Sales INC. | $38.68 | 2024 | Teligen |
| Therapeuticsmd, INC. | $29.58 | 2022 | |
| Ethicon US, LLC | $25.86 | 2022 | |
| Biogen, INC. | $25.42 | 2025 | Zurzuvae |
| Ortho-Clinical Diagnostics, INC. | $21.49 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $20.75 | 2025 | Gemtesa |
| Mayne Pharma Commercial LLC | $19.64 | 2023 | |
| Vivus LLC | $17.74 | 2021 | |
| Scynexis, INC. | $15.01 | 2022 | |
| Minerva Surgical, INC | $13.60 | 2025 | |
| Exeltis, USA INC. | $13.07 | 2019 | |
| Assertio Therapeutics, INC. | $11.04 | 2020 | |
| Vertical Pharmaceuticals, LLC | $10.87 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Locke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.